BNP Paribas Asset Management’s Arbutus Biopharma ABUS Stock Holding History

BNP Paribas Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11K	Sell	2,293 -1,473	-39%	-$6.47K	﹤0.01%	2198
2026 Q1	$16.9K	Buy	3,766 +1,367	+57%	+$5.98K	﹤0.01%	2081
2025 Q4	$12K	Buy	2,399 +468	+24%	+$2.1K	﹤0.01%	2084
2025 Q3	$9K	Buy	1,931 +175	+10%	+$643	﹤0.01%	1654
2025 Q2	$5K	Buy	+1,756	New	+$5.83K	﹤0.01%	1967
2015 Q3	–	Sell	-212,934	Closed	-$2.52M	–	1006
2015 Q2	$2.52M	Sell	212,934 -121,241	-36%	-$1.85M	0.02%	659
2015 Q1	$5.83M	Buy	+334,175	New	+$6.85M	0.04%	442

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Asset Management's ABUS Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Arbutus Biopharma (ABUS) stake by 39% in Q2 2026, selling an estimated $6.47K and leaving 2,293 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #2198.

BNP Paribas Asset Management first reported a position in ABUS in Q1 2015 and has held it in 7 quarters since. The position peaked at $5.83M in Q1 2015. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

BNP Paribas Asset Management held 2,293 shares of Arbutus Biopharma worth $11K as of Q2 2026.
BNP Paribas Asset Management sold 1,473 Arbutus Biopharma shares in Q2 2026, an estimated $6.47K.
Arbutus Biopharma made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2198 holding.
BNP Paribas Asset Management first reported a position in Arbutus Biopharma in Q1 2015 and has held it in 7 quarters since.
BNP Paribas Asset Management's Arbutus Biopharma position peaked at $5.83M in Q1 2015.
176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.